

CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID:

DRAWN

RECEIVED : 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status	Einal	Results	Biological Reference Interval	Unite
i lest Report Status	FILIAL	Nesuls	Didiodical Reference Tillerval	Ullita

ABHA NO

,=			
ŀ	HAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP A	BOVE 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	14.2	12.0 - 15.0	g/dL
METHOD: CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT	5.27 High	3.8 - 4.8	mil/μL
METHOD : FLUORESCENCE FLOW CYTOMETRY	C CO	4.0 10.0	th ou /ul
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	6.68	4.0 - 10.0	thou/μL
PLATELET COUNT	316	150 - 410	thou/µL
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY	310	130 410	ωσω, μ=
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	43.8	36 - 46	%
METHOD: CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	83.1	83.0 - 101.0	fL
METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	27.0	27.0	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.0	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN	32.4	31.5 - 34.5	g/dL
CONCENTRATION (MCHC)	32.4	31.3 - 34.3	9/ 4L
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	16.5 High	11.6 - 14.0	%
METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	45.0		
MENTZER INDEX	15.8		
MEAN PLATELET VOLUME (MPV)	11.5 High	6.8 - 10.9	fL
METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	64	40 - 80	%
METHOD : FLUORESCENCE FLOW CYTOMETRY	ОT	40 00	70
LYMPHOCYTES	29	20 - 40	%
METHOD : FLUORESCENCE FLOW CYTOMETRY	-	- -	
MONOCYTES	5	2 - 10	%

Dr. Sushant Chikane

Consultant Pathologist





Page 1 Of 26





PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







Female

PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138379 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0065XC002461 AGE/SEX

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

:54 Years

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
METHOD: FLUORESCENCE FLOW CYTOMETRY			
EOSINOPHILS	1	1 - 6	%
METHOD: FLUORESCENCE FLOW CYTOMETRY			
BASOPHILS	1	0 - 1	%
METHOD: FLUORESCENCE FLOW CYTOMETRY			
ABSOLUTE NEUTROPHIL COUNT	4.28	2.0 - 7.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	1.94	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.33	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.07	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER			•
ABSOLUTE BASOPHIL COUNT	0.07	0.02 - 0.10	thou/µL
METHOD : CALCULATED PARAMETER	2.2.	5.5= 5.=5	
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.2		
METHOD : CALCULATED			

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Sushant Chikane **Consultant Pathologist**



Page 2 Of 26



PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







REF. DOCTOR: SELF PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT

CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID:

ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21

REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval Final** Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 31 High 0 - 20mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

Non-diabetic Adult < 5.7 HBA1C 5.4 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: ION-EXCHANGE HPLC

108.3 mg/dL ESTIMATED AVERAGE GLUCOSE(EAG) < 116

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Sushant Chikane **Consultant Pathologist**



Page 3 Of 26

PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







REF. DOCTOR: SELF PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT

CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: RECEIVED: 29/03/2024 10:01:21 ABHA NO REPORTED :30/03/2024 15:24:13

DRAWN

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

- **HbA1c Estimation can get affected due to :**1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test résults.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Sushant Chikane **Consultant Pathologist** Page 4 Of 26







Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21

REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP В

METHOD: HAEMAGGLUTINATION (AUTOMATED)

RH TYPE **POSITIVE**

METHOD: HAEMAGGLUTINATION (AUTOMATED)

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane **Consultant Pathologist**





Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India

Tel: 9111591115, Fax: 022 - 67801212 CIN - U74899PB1995PLC045956





Page 5 Of 26



 CODE/NAME & ADDRESS : C000138379
 ACCESSION NO : 0065XC002461
 AGE/SEX : 54 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

i PATIENT ID : KADGF15046965.

------ RADGI 130

CLIENT PATIENT ID: ABHA NO : SD AMAN

DRAWN :

RECEIVED : 29/03/2024 10:01:21 REPORTED : 30/03/2024 15:24:13

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 96 Normal <100 mg/dL

Impaired fasting glucose:100 to

125

Diabetes mellitus: > = 126 (on

more than 1 occassion) (ADA guidelines 2021)

METHOD: SPECTROPHOTOMETRY HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 97 Normal <140 mg/dL

Impaired glucose tolerance:140 to 199 Diabetes mellitus: > = 200 (on more than 1 occassion)

ADA guideline 2021

METHOD: SPECTROPHOTOMETRY HEXOKINASE

LIPID PROFILE WITH CALCULATED LDL, SERUM

CHOLESTEROL, TOTAL 179 Desirable: < 200 mg/dL

Borderline : 200 - 239 High : > / = 240

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES 190 High Normal: < 150 mg/dL

Borderline high: 150 - 199

High: 200 - 499 Very High: >/= 500

METHOD: SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

HDL CHOLESTEROL 36 Low At Risk: < 40 mg/dL

Desirable: > or = 60

METHOD: SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZYMATIC COLORIMETRIC

Dr. Apeksha Sha

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

Dr/.

Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab





Page 6 Of 26

View Details

View Report



Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062

Maharashtra, India







PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : KADGF15046965 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 29/03/2024 10:01:21 DELHI ABHA NO REPORTED :30/03/2024 15:24:13 **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
CHOLESTEROL LDL	105 High	Optimal: < 100 mg/dL Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190
METHOD: CALCULATED PARAMETER		, 5
NON HDL CHOLESTEROL	143 High	Desirable: < 130 mg/dL Above Desirable: 130 -159 Borderline High: 160 - 189 High: 190 - 219 Very high: > / = 220
METHOD: CALCULATED PARAMETER		, -
VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED PARAMETER	38.0 High	< or = 30.0 mg/dL
CHOL/HDL RATIO	5.0 High	Low Risk: $3.3 - 4.4$ Average Risk: $4.5 - 7.0$ Moderate Risk: $7.1 - 11.0$ High Risk: > 11.0
METHOD: CALCULATED PARAMETER		
LDL/HDL RAΠO	2.9	Desirable/Low Risk: 0.5 - 3.0 Borderline/Moderate Risk: 3.1 - 6.0 High Risk: > 6.0
METHOD: CALCULATED PARAMETER		

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Misk Stratification for	ASC VD (Atheroscierotte cardiovascular disease) by Elpid Association of India
Risk Category	
Extreme risk group	A.CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.
	Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ
	damage. 3. CKD stage 3B or 4. 4. LDL > 190 mg/dl 5. Extreme of a single risk factor. 6. Coronary
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist**

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab







PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India Tel: 9111591115, Fax: 022 - 67801212 CIN - U74899PB1995PLC045956





Page 7 Of 26



CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21

REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

Moderate Risk	2 major ASCVD risk factors	
Low Risk	0-1 major ASCVD risk factors	
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors		
1. Age $>$ or $= 45 \text{ yea}$	ars in males and $>$ or $= 55$ years in females	3. Current Cigarette smoking or tobacco use
2. Family history of	premature ASCVD	4. High blood pressure
5. Low HDL		

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR $=$ 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><OR = 60</td><td>> 30</td><td>>60</td></or>	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD: SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO METHOD	0.38	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.19	< or = 0.3	mg/dL
METHOD: SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZ BILIRUBIN, INDIRECT	0.19	0.0 - 0.9	mg/dL
METHOD : CALCULATED PARAMETER TOTAL PROTEIN	7.7	6.0 - 8.0	g/dL
METHOD: SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGEN ALBUMIN	4.4	3.97 - 4.94	g/dL
METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DY GLOBULIN	7E BINDING 3.3	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.3	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE(AST/SGOT)	18	Upto 32	U/L
METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ALANINE AMINOTRANSFERASE (ALT/SGPT)	25	Upto 33	U/L
METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ALKALINE PHOSPHATASE	E ACTIVATION(P5P) - IFCC 72	35 - 104	U/L

METHOD: SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist**

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab





Page 8 Of 26



PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KADGF15046965

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 29/03/2024 10:01:21 DELHI

ABHA NO REPORTED :30/03/2024 15:24:13 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

U/L GAMMA GLUTAMYL TRANSFERASE (GGT) 29 < 40

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCC

U/L LACTATE DEHYDROGENASE < 223 176

METHOD: SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 10 6 - 20mg/dL

METHOD: SPECTROPHOTOMETRY, UREASE-COLORIMETRIC

CREATININE, SERUM

1.03 0.60 - 1.10mg/dL CREATININE

METHOD: SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED

BUN/CREAT RATIO

9.50 8 - 15 **BUN/CREAT RATIO**

METHOD: CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID 7.5 High 2.4 - 5.7mg/dL

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN g/dL 7.7 6.0 - 8.0

METHOD: SPECTROPHOTOMETRY, COLORIMETRIC-BIURET, REAGENT BLANK, SERUM BLANK

ALBUMIN, SERUM

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab



Page 9 Of 26



PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

RECEIVED : 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

<u> </u>	<u> </u>	
Results	Biological Reference Interv	al Units
4.4	3.97 - 4.94	g/dL
DYE BINDING		
2.2	20 25	ام/
3.3	2.0 - 3.5	g/dL
141	136 - 145	mmol/L
4.60	3.5 - 5.1	mmol/L
104	98 - 106	mmol/L
	4.4 DYE BINDING 3.3 141 4.60	4.4 3.97 - 4.94 3.3 2.0 - 3.5 141 136 - 145 4.60 3.5 - 5.1

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist**

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab



Page 10 Of 26



PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







REF. DOCTOR: SELF PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT

CODE/NAME & ADDRESS: C000138379 ACCESSION NO : 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

PATIENT ID

: KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED: 30/03/2024 15:24:13

Test Report Status Results Biological Reference Interval Units **Final**

Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, or al contraceptives.

Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.

Increased in: Massive hemolysis. severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole

Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.

Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadre no corticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.

Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction. Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab



Page 11 Of 26

PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







REF. DOCTOR: SELF PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT

CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID:

ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) **Causes of decreased** level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab

Page 12 Of 26

PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India

Tel: 9111591115, Fax: 022 - 67801212 CIN - U74899PB1995PLC045956

ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS





CODE/NAME & ADDRESS: C000138379 :54 Years ACCESSION NO: 0065XC002461 AGE/SEX Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, URINE

PALE YELLOW **COLOR**

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PH	7.0	4.6 - 8.0
SPECIFIC GRAVITY	1.000 Low	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NOT DETECTED	
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	0-1	0-5	/HPF
EPITHELIAL CELLS	3-5	0-5	/HPF

NOT DETECTED **CASTS** NOT DETECTED **CRYSTALS**

BACTERIA NOT DETECTED NOT DETECTED YEAST NOT DETECTED NOT DETECTED

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM. (PH-DOUBLE INDICATOR, SP. GRAVITY-IONIC CONCEN, GLUCOSE-GOD/POD, PROTEIN- ERROR OF INDICATORS, KETONE-LEGAL'S, BLOOD- PEROXIDASE ACTIVITY-HB, BILIRUBIN-DIAZOTIZATION, UROBILINOGEN-DIAZOTIZATION, NITRITE-GRIESS, LEUKOCYTES- ESTERASES ACTIVITY)

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist**

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab



Page 13 Of 26



PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KADGF15046965

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 29/03/2024 10:01:21

DELHI ABHA NO REPORTED :30/03/2024 15:24:13 **NEW DELHI 110030** 8800465156

Test Report Status Final Results **Biological Reference Interval** Units

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions			
Proteins	Inflammation or immune illnesses			
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind			
	of kidney impairment			
Glucose	Diabetes or kidney disease			
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst			
Urobilinogen	Liver disease such as hepatitis or cirrhosis			
Blood	Renal or genital disorders/trauma			
Bilirubin	Liver disease			
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary			
	tract infection and glomerular diseases			
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either			
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by			
	genital secretions			
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or			
	bladder catheters for prolonged periods of time			
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,			
	interaction with Bence-Jones protein			
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases			
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous			
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl			
	oxalate or the gastrointestinal lipase inhibitor or listat, ingestion of			
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice			
Uric acid	arthritis			
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.			
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis			

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist**

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab







PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India

Tel: 9111591115, Fax: 022 - 67801212 CIN - U74899PB1995PLC045956





Page 14 Of 26



CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** Units **Final**

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

TWO UNSTAINED CERVICAL SMEARS RECEIVED SPECIMEN TYPE

(2CX-8515)

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY REPORTING SYSTEM

SMEARS ARE SATISFACTORY FOR EVALUATION. SPECIMEN ADEQUACY

THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW **MICROSCOPY**

INTERMEDIATE SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, FEW CLUSTERS OF ENDOCERVICAL CELLS IN THE

MODERATE BACKGROUND OF POLYMROPHS.

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY INTERPRETATION / RESULT

REACTIVE CELLULAR CHANGES ASSOCIATED WITH INFLAMMATION

(INCLUDES TYPICAL REPAIR - MODERATE INFLAMMATION)

ENDOMETRIAL CELLS (IN A WOMAN >/= 45

YRS)

Comments

Suggestions / Guidelines: (REF: THE BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY, 2014, 3rd Edition) ADVISED REPEAT SMEAR, AFTER TREATMENT OF INFLAMMATION.

- 1) Please note papanicolaou smear study is a screening procedure for cervical cancer with inherent false negative results, hence should be interpreted with caution.
- 2) No cytologic evidence of hpv infection in the smears studied.
- 3) Primary screening of papanicolaou smears is carried out by cytotechnologist with 100% rescreening and reporting by surgical pathologist.

Dr.Priyanka Kembhavi (Reg.No.2014/05/2240) Histopathologist





Page 15 Of 26

PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

RECEIVED: 29/03/2024 10:01:21

REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

MICROSCOPIC EXAMINATION, STOOL

REMARK SAMPLE NOT RECEIVED

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION			
Pus cells	Pus in the stool is an indication of infection			
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis			
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.			
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.			
Charcot-Leyden crystal	Parasitic diseases.			
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.			
Frank blood	Bleeding in the rectum or colon.			
Occult blood	Occult blood indicates upper GI bleeding.			
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.			
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.			
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.			
pН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.			

ADDITIONAL STOOL TESTS:

Dr. Ekta Patil **Microbiologist**

Page 16 Of 26





Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21

REPORTED: 30/03/2024 15:24:13

Biological Reference Interval Test Report Status Results Units <u>Final</u>

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- 2. Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to 4. overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array 5. Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Ekta Patil Microbiologist



Page 17 Of 26





Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India







 CODE/NAME & ADDRESS : C000138379
 ACCESSION NO : 0065XC002461
 AGE/SEX : 54 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

| |PATIENT ID : KADGF15046965

CLIENT PATIENT ID:

ABHA NO :

DRAWN ·

RECEIVED : 29/03/2024 10:01:21

REPORTED :30/03/2024 15:24:13

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

T3 113.0 Non-Pregnant Women ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

T4 7.70 Non-Pregnant Women µg/dL

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

TSH (ULTRASENSITIVE) 1.960 NonPregnant Women 0.27- µIU/mL

4.20

Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

METHOD: SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

Marin

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist Dr/.

Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab





Page 18 Of 26

View Details



PERFORMED AT :

Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062

Maharashtra, India Tel: 9111591115, Fax: 022 - 67801212

CIN - U74899PB1995PLC045956





8800465156



PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID

: KADGF15046965 DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 29/03/2024 10:01:21 DELHI ABHA NO REPORTED :30/03/2024 15:24:13 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist**

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai Reference Lab







PERFORMED AT:

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

Maharashtra, India

Tel: 9111591115, Fax: 022 - 67801212 CIN - U74899PB1995PLC045956





Page 19 Of 26



 CODE/NAME & ADDRESS : C000138379
 ACCESSION NO : 0065XC002461
 AGE/SEX : 54 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO : DRAWN :

RAWN :

RECEIVED : 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

ECG

ECG TACHYCARDIA OTHERWISE NORMAL

MAMOGRAPHY (BOTH BREASTS)

MAMOGRAPHY BOTH BREASTS NO FOCAL PARENCHYMAL LESION SEEN

BIRADS-I

MEDICAL HISTORY

RELEVANT PRESENT HISTORY

RELEVANT PAST HISTORY

RELEVANT PERSONAL HISTORY

MENSTRUAL HISTORY (FOR FEMALES)

RELEVANT FAMILY HISTORY

HYPERTENSION.

HISTORY OF MEDICATIONS

HYPERTENSION.

NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.61 mts WEIGHT IN KGS. 73 Kgs

BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

Dr.Rajesh Nayak Consultant Radiologist





Page 20 Of 26

View Details

View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No. 88, Road No. 15,Midc Estate,Andheri (East) Mumbai, 400093 Maharashtra, India

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956





CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL **NORMAL** PHYSICAL ATTITUDE **OVERWEIGHT** GENERAL APPEARANCE / NUTRITIONAL

STATUS

BUILT / SKELETAL FRAMEWORK AVERAGE FACIAL APPEARANCE **NORMAL NORMAL** SKIN UPPER LIMB **NORMAL NORMAL** LOWER LIMB **NECK NORMAL**

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

NOT ENLARGED THYROID GLAND

CAROTID PULSATION **NORMAL NORMAL TEMPERATURE**

REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT **PULSE**

RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

BP 150/80 MM HG mm/Hg

> (SUPINE) **NORMAL**

PERICARDIUM APEX BEAT **NORMAL HEART SOUNDS NORMAL ABSENT MURMURS**

RESPIRATORY SYSTEM

NORMAL SIZE AND SHAPE OF CHEST

Dr.Rajesh Nayak **Consultant Radiologist**



Page 21 Of 26

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No. 88, Road No. 15, Midc Estate, Andheri (East) Mumbai, 400093 Maharashtra, India

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956





CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

SYMMETRICAL MOVEMENTS OF CHEST **NORMAL** BREATH SOUNDS INTENSITY

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS **ABSENT**

PER ABDOMEN

NORMAL **APPEARANCE** VENOUS PROMINENCE **ABSENT**

NOT PALPABLE LIVER SPLEEN NOT PALPABLE ABSENT HERNIA

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS **NORMAL NORMAL** CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS **NORMAL** SENSORY SYSTEM MOTOR SYSTEM **NORMAL REFLEXES NORMAL**

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

NORMAL CONJUNCTIVA EYELIDS NORMAL

Dr.Rajesh Nayak

Consultant Radiologist

Page 22 Of 26





PERFORMED AT:

Agilus Diagnostics Ltd. Plot No. 88, Road No. 15, Midc Estate, Andheri (East) Mumbai, 400093 Maharashtra, India

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956





 CODE/NAME & ADDRESS : C000138379
 ACCESSION NO : 0065XC002461
 AGE/SEX : 54 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

| |PATIENT ID : KADGF15046965

CLIENT PATIENT ID:

ABHA NO :

DRAWN :

RECEIVED : 29/03/2024 10:01:21 REPORTED : 30/03/2024 15:24:13

Test Report Status <u>Final</u> Results Biological Reference Interval Units

EYE MOVEMENTS NORMAL CORNEA NORMAL

DISTANT VISION RIGHT EYE WITHOUT REDUCE VISUAL ACUITY (6/9)

GLASSES

DISTANT VISION LEFT EYE WITHOUT REDUCE VISUAL ACUITY (6/9)

GLASSES

NEAR VISION RIGHT EYE WITHOUT GLASSES REDUCE VISUAL ACUITY (N/10)
NEAR VISION LEFT EYE WITHOUT GLASSES REDUCE VISUAL ACUITY (N/10)
COLOUR VISION OUT OF 17 NUMBERED PLATES 17

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL NORMAL TYMPANIC MEMBRANE NORMAL

NOSE NO ABNORMALITY DETECTED

SINUSES NORMAL

THROAT NO ABNORMALITY DETECTED

TONSILS NOT ENLARGED

SUMMARY

RELEVANT HISTORY

RELEVANT GP EXAMINATION FINDINGS

RELEVANT LAB INVESTIGATIONS

RAISED ESR(31)
RAISED RBCC(5.27)

RAISED RECC(3.27)
RAISED TRIGLYCERIDES(190)
LOW HDL CHOLESTEROL(36)

RAISED NON HDL CHOLESTEROL(143)
RAISED DIRECT LDL CHOLESTEROL(105)

RELEVANT NON PATHOLOGY DIAGNOSTICS USG: MILD FATTY LIVER

RIGHT RENAL CALCULUS.

2D ECHO: GRADE I LV DIASTOLIC DYSFUNCTION
REMARKS / RECOMMENDATIONS
REGULAR PHYSICAL EXERCISES / LOW CALORIC DIET
REDUCE FATTY AND PROCESSED FOOD IN DIET

hr.

Dr.Rajesh Nayak Consultant Radiologist



Page 23 Of 26

View Details

View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No. 88, Road No. 15,Midc Estate,Andheri (East) Mumbai, 400093

Maharashtra, India

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PI C045956





CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Biological Reference Interval Test Report Status <u>Final</u> Results Units

Dr.Rajesh Nayak **Consultant Radiologist**





Page 24 Of 26



Agilus Diagnostics Ltd. Plot No. 88, Road No. 15, Midc Estate, Andheri (East) Mumbai, 400093 Maharashtra, India

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956





CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID:

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

ABHA NO

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

MILD FATTY LIVER.RIGHT RENAL CALCULUS.

TMT OR ECHO

CLINICAL PROFILE

GRADE I LV DIASTOLIC DYSFUNCTION

Interpretation(s) MEDICAL

HISTORY-********** THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr.Rajesh Nayak **Consultant Radiologist**



Page 25 Of 26

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No. 88, Road No. 15, Midc Estate, Andheri (East) Mumbai, 400093 Maharashtra, India

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956





REF. DOCTOR: SELF PATIENT NAME: KADGATOOR SHEETAL VENKATESMURT

CODE/NAME & ADDRESS: C000138379 ACCESSION NO: 0065XC002461 AGE/SEX :54 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KADGF15046965

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 29/03/2024 10:01:21 REPORTED :30/03/2024 15:24:13

Test Report Status Results Biological Reference Interval Units **Final**

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr.Rajesh Nayak **Consultant Radiologist**





Page 26 Of 26



PERFORMED AT:

Agilus Diagnostics Ltd. Plot No. 88, Road No. 15, Midc Estate, Andheri (East) Mumbai, 400093 Maharashtra, India

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PI C045956

